A review of the state of cervical cancer: updates from prevention to recurrent disease

Curr Opin Obstet Gynecol. 2024 Feb 1;36(1):28-33. doi: 10.1097/GCO.0000000000000918. Epub 2023 Oct 11.

Abstract

Purpose of review: To summarize the recent updates in cervical cancer from prevention and early detection to the management of early stage and recurrent disease as well as future areas of exploration.

Recent findings: The importance of the human papilloma virus vaccine and screening continue to make an impact in reducing the global burden of cervical cancer. In early-stage, low risk disease, new studies have demonstrated the role of less radical surgery with similar disease related outcomes. Efforts to improve outcomes in locally advanced cervical cancer have been reported. The incorporation of adjuvant chemotherapy, novel agents and checkpoint inhibitors, with the latter impacting disease free survival. In advanced/recurrent disease, the role of immunotherapy continues to make an impact and, in addition to recurrent disease, has now moved to the frontline for patients with programmed cell death ligand 1 expression. Tisotumab vedotin, an antibody drug conjugate, and other novel agents continue to be studied in this setting.

Summary: In this review, we discuss prevention measures and the outcomes of recent trials in all stages of cervical cancer. As therapies continue to evolve, ongoing trials and new areas of exploration will continue to identify opportunities to improve survival in cervical cancer.

Publication types

  • Review

MeSH terms

  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Uterine Cervical Neoplasms* / drug therapy
  • Uterine Cervical Neoplasms* / prevention & control